Cancer Breakthroughs 2020 Milestone: The Nation's First Neoepitope Antibody Immunotherapy Phase II Trial Demonstrating Safety and Prolonged Survival in Patients with Metastatic End-Stage Colon Cancer

Clinical investigators from Moffitt and Walter Reed Army Institute present data of first Phase II Neoepitope Antibody Immunotherapy Clinical Trial completed at John’s Hopkins, Duke and Moffitt as a potential new immunotherapy treatment for cancer care, a Cancer Breakthroughs 2020 milestone. 

Read More

Cancer Breakthroughs 2020 Milestone: NantWorks Announces NantCare Oncology Solutions, A Technology Support Platform for Community Oncology Practices in the Oncology Care Model (OCM)

NantCare, a member of the NantWorks family of companies responsible for operationalizing the Cancer Breakthroughs 2020 and QUILT programs, today announced its active engagement with community oncology practices by providing a combination of technology, access to clinical trials and administrative support to optimize community oncology practices’ compliance in the Oncology Care Model (OCM).

Read More

Cancer Breakthroughs 2020 Milestone: Announcing Launch of the Nation's Largest Pediatric Brain Tumor Atlas

NantHealth, Inc.(Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, the Chan Soon-Shiong Institute of Molecular Medicine and the collaborators of the Breakthroughs today announced that they are embarking on one of the world’s most ambitious pediatric sequencing discovery projects to date. This initiative will focus on the largest killer of pediatric cancer patients today: childhood brain tumors.

Read More

Cancer Breakthroughs 2020 and NantHealth Launch a Global Inflammatory Breast Cancer Working Group to Investigate Personalized Immunotherapeutic Treatment Options for Rare Disease

Cancer Breakthroughs 2020, the nation’s most comprehensive cancer collaborative initiative, today announced the formation of the Inflammatory Breast Cancer Working Group. The team consists of physicians, researchers and oncology professors from across the nation who have come together to focus their collective wisdom and expertise to identify and develop the most effective cancer-directed immunotherapy treatments for inflammatory breast cancer (IBC)

Read More

NantHealth Announces New Expanded Coverage with Self-Insured Employers, ‎ Insurance Payers, and Health Systems for GPS Cancer Test

NantHealth, LLC announced the expanded adoption of GPS Cancer, a unique comprehensive  molecular test to help oncology care providers guide treatment strategies for cancer care, by partnering with major self-insurers that have agreed to cover the costs for their employees requiring this test. 

Read More

Dr. Patrick Soon-Shiong to Give Keynote Address and NantKwest to Present at the Bank of America Merrill Lynch 2016 Health Care Conference

NantKwest, Inc (Nasdaq:NK), today announced that Dr. Patrick Soon-Shiong, NantKwest’s Chairman and CEO will be giving the Keynote address and NantKwest will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada on Tuesday, May 10, 2016.

Read More

Precision Biologics, a NantWorks Company, to Present Combination Immunotherapy of Novel Neo-Epitope Anitbody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016

Precision Biologics will present a poster titled, “Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes” at the American Association for Cancer Research (AACR) Annual Meeting 2016.

Read More